Who are we?
Tzamal has been at the forefront of medical technology representing some of the most distinguished medical device companies in the world, for more than 35 years. During its first 25 years, the company represented established companies and focused on direct sales. Companies which chose Tzamal to represent them include Johnson & Johnson, Ohmeda (B&D) and Schneider (Pfizer).
Medical Innovation Specialists
Just over a decade ago Tzamal embarked on a bold and new path and therefore underwent a major reorganization. The company decided to devote almost a third of its resources to representing up and coming med-techs offering unique, innovative solutions. An intensive marketing program was introduced, specifically designed to familiarize the medical community with medical innovations. Thanks to this strategy, Tzamal is today recognized for its expertise in promoting and achieving sales for young medical technology innovators. The company is proud of its unique ability to break-down barriers and guide hospital administrators throughout replacement of obsolete medical technologies with innovative ones.
Putting Patients First
Stunning results have shown the new company succeeded in surpassing the sales peak of its predecessor within half the time. Today Tzamal enjoys annual sales of over $27 million and growing. The secret of our success lies in great part in our continuous pursue for better patient care as a main goal..Our commitment to state-of-the art health care is what drives our outstanding results.
Tzamal is active in most major med-tech markets via its six subsidiaries:
Tzamal Jakobsohn – Innovative devices and technology for surgery, orthopedics, cardiology, neurosurgery and spinal applications.
Tzamal Bio-Pharma – Specialty biotechnologies and pharmaceuticals, orphan drugs for rare diseases
Tzamal M.P.VET – Veterinary products, technologies and equipment
Tzamal 2B Capital Medical Equipment – High-tech capital equipment for all areas of healthcare industry
Tzamal Medicare – Innovative technology for primary and home care
Tzamal D-Chem Laboratories – Chemicals for research
Actively Advancing Innovation
Besides marketing existing products\companies, Tzamal is also greatly involved in development of innovative new medical technologies by mentoring and financing promising medical technology start-ups in a wide variety of fields. Via its subsidiary Tzamal Investments the company is closely guiding and financing some two dozen young companies.
Drugs Disributed by Tzamal Bio-Pharma Ltd
Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml. VIAL FOR INJECT: 1 x 12.5 mg/50 ml
INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
mg/ml). Initial: 0.4 μg/kg/min of
diluted sol. by I.V. Then 0.1 μg/kg/min.
In comb. with heparin in unstable
ang. or non-Q-wave M.I., prevent card.
ischem. events, acute coronary syndr.
(incl. medically managed and
undergoing PTCA or atherectomy). See
Antiarrhythmics Class I and III. Vernakalant (as HCl) 20 mg/ml. VIAL: 1×10, 25 ml. Recom. init. infus. is 3 mg/kg to be infus. over a 10 min. period. pts. weigh. ≥ 113 kg, do not exceed the max. init. dose of 339 mg (84.7 ml of 4 mg/ml sol.). If conver. to sinus rhythm does not occur within 15 min. after the end of the init. infus., a 2nd 10 min. infus. of 2 mg/kg may be admin. Pts. weigh. ≥ 113 kg, do not exceed the max. 2nd infus. of 226 mg (56.5 ml of 4 mg/ml sol.). Cumulative doses of greater than 5 mg/kg should not be admin. within 24 hrs. There are no clin. data on repeat doses after the
init. and 2nd infus. By 24 hrs. there
appears to be insignificant levels of
vernakalant. See lit.
Rapid conver. of recent onset atrial fibril.
to sinus rhythm in adults who are
hemodynamic. stable For non-surgery pts.: atrial fibril. ≤ 7 d. duration. For post-cardiac surgery pts.: atrial fibrill.≤ 3 d. duration.
C/I: Hypersen. Pts. with severe aortic
stenosis, pts. with systolic blood pressure
<100 mm Hg, and pts. with Heart fail. class
NYHA III and NYHA IV. Pts. with prolon. QT
at baseline (uncorrected > 440 msec), or
severe bradycar. sinus node dysfunc. or
2nd degree and 3rd degree heart block in
the absence of a pacemaker. Use of IV
rhythm control anti-arrhythmics (class I
and class III) within 4 hrs. prior to, as well
as in the first 4 hrs. after, drug admin.
Acute coron. synd. (includ. MI) within the
last 30 days.
DNA Polymerase Inhibitor. Ganciclovir 500 mg. VIALS: 1, 5. Adults: Initially 5mg/kg
every 12 hrs. (at a constant rate of 1
hr.), every 12 hrs. by I.V. inf. for 14 - 21
days. Maint: 6mg/kg dly. by I.V. infus. 5
days/wk. or 5 mg/kg dly. for 7 days/wk.
Only in the tmt. of CMV retinit. in
immunocompromised pts., prevent. CMV
dis. in transplant pts. at risk for CMV dis.
Alkylating Agent. Dacarbazine (as Citrate) 200, 500, 1000 mg/vial. SINGLE DOSE VIALS (Pwdr. for sol. for
inject./infus.): 1, 10 x 200 mg; (Pwdr. for
soln for infus.): 1, 10 x 500 mg, 1,000 mg.
Malign. melanoma: (as single agent):
200-250 mg/m2 bdy surface area/day)
I.V. for 5 days every 3 wks. Alt: Shortterm
infus. (over 15-30 mins). Also
possible: I.V. 850 mg/m2 on day 1, then
once every 3 wks. Hodgkin’s dis: 375
mg/m2 I.V. every 15 days in comb. with
doxorubicin, bleomycin and
vinblastine. See lit.
Malign. melanoma, Hodgkin’s dis.
C/I: Hypersens., pregn., lact., leucopen.,
and/or thrombocytopen., severe liver/